Back

Transcription factor 19 is an androgen responsive gene that modulates vessel homeostasis and sustains metastatic prostate cancer

Carracedo, A.; Ercilla, A.; Crespo, J. R.; Garcia-Longarte, S.; Fidalgo, M.; Martin-Martin, N.; Carlevaris, O.; Astobiza, I.; Fernandez-Ruiz, S.; Guiu, M.; Barcena, L.; Mendizabal, I.; Aransay, A. M.; Graupera, M.; Gomis, R. R.

2025-02-08 cancer biology
10.1101/2025.02.04.636232 bioRxiv
Show abstract

Prostate cancer is a prevalent tumor type that, despite being highly curable, progresses to metastatic disease in a fraction of patients, thus accounting for more than 350.000 annual deaths worldwide. In turn, uncovering the molecular insights of metastatic disease is instrumental to improve the survival rate of prostate cancer patients. By means of gene expression metanalysis in multiple prostate cancer patient cohorts, we identified a set of genes that are differentially expressed in aggressive prostate cancer. Transcription factor 19 (TCF19) stood out as an unprecedented epithelial gene upregulated in metastatic disease, with prognostic potential and associated with the activity of androgen receptor. By combining computational and empiric approaches, our data revealed that TCF19 is required for full metastatic capacity and its depletion influences core cancer-related processes, such as vascular permeability, supporting the role of this gene in the dissemination of prostate tumor cells.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Oncogene
○ 85 papers in training set
Top 0.1%
9.4%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 19%
9.4%
Similar papers in this journal
3
Scientific Reports
○ 3612 papers in training set
Top 11%
6.5%
Similar papers in this journal
4
Journal of Experimental & Clinical Cancer Research
○ 25 papers in training set
Top 0.1%
6.5%
Similar papers in this journal
5
Cell Death & Disease
147 papers in training set
Top 0.3%
6.1%
6
Communications Biology
○ 993 papers in training set
Top 2%
5.3%
7
Cancers
○ 213 papers in training set
Top 1%
4.7%
8
eLife
● 5828 papers in training set
Top 27%
4.7%
50% of probability mass above
9
Frontiers in Oncology
○ 103 papers in training set
Top 0.7%
4.7%
10
Cancer Research
● 130 papers in training set
Top 0.9%
4.2%
11
Cell Reports
○ 1498 papers in training set
Top 9%
4.2%
12
Science Advances
● 1243 papers in training set
Top 12%
3.1%
13
iScience
○ 1154 papers in training set
Top 12%
2.3%
14
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.7%
1.9%
15
Molecular Cancer Research
● 49 papers in training set
Top 0.7%
1.7%
16
British Journal of Cancer
○ 49 papers in training set
Top 0.8%
1.7%
17
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 31%
1.5%
18
Neoplasia
○ 23 papers in training set
Top 0.5%
1.3%
19
International Journal of Cancer
○ 49 papers in training set
Top 0.8%
1.3%
20
Cells
○ 249 papers in training set
Top 5%
1.1%
21
Cell Death Discovery
○ 58 papers in training set
Top 1%
1.0%
22
Life Science Alliance
● 285 papers in training set
Top 7%
1.0%
23
Theranostics
● 37 papers in training set
Top 1%
0.8%
24
Cell Reports Medicine
○ 153 papers in training set
Top 5%
0.8%
25
Nature Genetics
○ 286 papers in training set
Top 6%
0.6%
26
Molecular Oncology
○ 55 papers in training set
Top 2%
0.6%
27
Molecular Cancer Therapeutics
● 40 papers in training set
Top 1.0%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.